A Phase IIa Repeat Dose AXP1275 vs Placebo Cross-over Trial With Pulmonary Allergen Challenge in Adults With Asthma

Phase 2

Completed

• Conditions: Atopic Asthma
• Interventions: Drug: AXP1275 matching placebo; Drug: AXP1275

• Registration Number: NCT01890161
• Lead Sponsor: Axikin Pharmaceuticals, Inc.

Brief Summary

This is the first study in human patients with asthma that the sponsor is conducting in order to evaluate if there are signals that the investigational medication, AXP1275, may be a safe and effective treatment for asthma. The results of this study may help the sponsor to design additional studies.

Detailed Description

This 2-way, randomized, double-blind crossover study in subjects with mild to moderate atopic asthma is designed to compare the responses to allergen and methacholine challenges within the same subject after approximately 2 weeks of treatment with AXP1275 50 mg or placebo. A total of 20 subjects with asthma with a dual (early and late) asthmatic response to an inhaled aeroallergen will be randomized to 1 of 2 treatment sequences (placebo then AXP1275 or AXP1275 then placebo) in a double-blind fashion to receive either oral AXP1275 or matching placebo, once-daily, for 14 days. The washout period between the 2 treatment periods will be 14 to 21 days.

A post-treatment follow-up visit will occur 14 ± 3 days after completion of the second treatment period.

Study Timeline

• Study First Submitted: 2013-06-26
• Study First Submitted QC: 2013-06-27
• Study First Posted: 2013-07-01
• Study Start: 2013-08
• Primary Completion: 2014-04
• Study Completion: 2014-04
• Status Verified: 2016-01
• Disposition First Submitted: 2016-01-08
• Disposition First Submitted QC: 2016-01-08
• Last Update Submitted: 2016-01-08
• Disposition First Posted: 2016-02-05
• Last Update Posted: 2016-02-05

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 21

Inclusion Criteria

1. Age 18 to 64 years (inclusive).
2. Male or female.
3. If male, is surgically sterile (vasectomy) or agrees to comply with required contraceptive measures.
4. If female, not pregnant (or lactating), as evidenced by a negative serum pregnancy test, and is either surgically sterile (hysterectomy, bilateral ovariectomy, or bilateral tubal ligation), or if a female of childbearing potential, agrees to comply with required contraceptive measures.
5. History of episodic wheeze and shortness of breath with a prebronchodilator FEV1 ≥70% of predicted at screening.
6. Asthma symptoms treated (if necessary) only with intermittent short-acting ß-agonist therapy by inhalation.
7. Demonstration of a positive wheal reaction on skin prick testing to at least 1 common aeroallergen at screening.
8. Screening inhalational allergen challenge response demonstrating that the subject experiences both an early asthmatic response (EAR) and a late asthmatic response (LAR).
9. Methacholine PC20 ≤16 mg/mL at screening.
10. No history of smoking within 6 months of screening, and with a total pack year history of ≤10 pack years.
11. 12-lead ECG recording without signs of clinically relevant pathology or showing no clinically relevant deviations as judged by the investigator.
12. All values for hematology, clinical chemistry, and urinalysis within the normal range, or if abnormal, are deemed not clinically significant by the investigator with documented agreement from the medical monitor.
13. Is able to give written informed consent.

Exclusion Criteria

1. Past or present disease which, as judged by the investigator, may affect the outcome of this study.
2. Respiratory tract infection and/or exacerbation of asthma within 4 weeks prior to the screening period.
3. Symptomatic allergic rhinitis. Those subjects with a history of allergic rhinitis may participate if asymptomatic at screening (and continue to be so at baseline on Day 1 prior to dosing) and if, in the opinion of the investigator, it is unlikely that disease exacerbation will occur during the course of the study.
4. History of life-threatening asthma.
5. Abnormal chest X-ray.
6. Use of oral, injectable, or dermal steroids within 3 months and/or inhaled steroids within 1 month of screening.
7. Use of cromoglycate, nedocromil, leukotriene receptor antagonists (zafirlukast, pranlukast, montelukast), and inhibitors of 5-lipoxygenase (zileuton) within 4 weeks of screening.
8. Use of immunosuppressives, anticoagulants (warfarin or heparin), or any medications that may interact with pharmacodynamic (PD) effects of AXP1275 within 4 weeks of screening.
9. Use of theophylline-containing agents (any type) and long-acting β2-agonists (salmeterol, formoterol) within 4 weeks of screening.
10. Positive screen for drug(s) of abuse (opiates, methadone, cocaine, amphetamines, cannabinoids, barbiturates, or benzodiazepines) or cotinine.
11. Positive for hepatitis B surface antigen, hepatitis C virus, or human immunodeficiency virus (HIV) 1/2.
12. Has participated in a clinical trial and has received an investigational product within 30 days prior to screening, or 5 elimination half lives of the investigational product, whichever is longer.
13. Has had significant blood loss (>500 mL) or donation of blood within 2 months prior to screening visit 1.
14. History of being unable to tolerate or complete methacholine or allergen challenge tests.
15. Subject is undergoing allergen desensitization therapy.
16. History of immunotherapy in the 3 years prior to screening or concurrently undergoing immunotherapy treatment.
17. Professional or ancillary personnel involved in the study.
18. Is not, in the opinion of the investigator, suitable for entry into the study.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: CROSSOVER

Arm && Interventions

Group	Intervention	Description
AXP1275 matching placebo	AXP1275 matching placebo	AXP1275 matching placebo (2 capsules) once daily for 14 days
AXP1275	AXP1275	AXP1275 50 mg (2 × 25-mg capsules) once daily for 14 days

Primary Outcome Measures

Name	Time	Method
Late Asthmatic Response	From 3 to 7 hours after allergen challenge on day 13 of both 14-day treatment periods	Area under the forced expiratory volume in 1 second (FEV1) curve from 3 to 7 hours after allergen challenge (AUC3-7h) on day 13 of both 14-day treatment periods.

Secondary Outcome Measures

Name	Time	Method
Late Asthmatic Response-Secondary	Between 3 to 7 hours after allergen challenge on day 13 of both 14-day treatment periods	Maximum percentage fall in FEV1 between 3 to 7 hours after allergen challenge on day 13 of both 14-day treatment periods.
Sputum eosinophil count	On days 12, 13, and 14 of both 14-day treatment periods	Induced sputum eosinophil count per mL of sputum on days 12, 13, and 14 of both 14-day treatment periods.
Total Asthmatic Response	Between 0 to 7 hours after allergen challenge on day 13 of both 14-day treatment periods	Minimum FEV1 and AUC of FEV1 between 0-7 hours (AUC0 7h) after allergen challenge on day 13 of both 14-day treatment periods.
Early Asthmatic Response	Between 0 to 2 hours after allergen challenge on day 13 of both 14-day treatment periods	Maximum percentage fall in FEV1 and AUC of FEV1 between 0 to 2 hours (AUC0-2h) after allergen challenge on day 13 of both 14-day treatment periods.
FEV1 comparison	At day 12, 13, and 14 of both 14-day treatment periods	For FEV1 values at each time point on day 12, 13, and 14, the difference between the two treatments will be calculated.
Sputum cell count (other)	On days 1, 12, 13, and 14 of both 14-day treatment periods	Induced sputum cell count per mL of sputum for cells other than eosinophils (including basophils) on days 1, 12, 13, and 14 of both 14-day treatment periods.
CCL13 and CCL17 concentrations	On days 12, 13, and 14 of both 14-day treatment periods	Comparison of the two treatments for changes in sputum concentrations of CCL13 and CCL17.
Maximum exhaled nitric oxide (eNO) and AUC of eNO	On days 13 and 14 of both 14-day treatment periods	Maximum eNO and AUC of eNO on days 13 and 14 (AUC0-24h) of both 14-day treatment periods.
eNO comparison	On days 13 and 14 of both 14-day treatment periods	For eNO values at each time point on day 13, and 14 of both 14-day treatment periods, the difference between the two treatments will be calculated.
Provocative concentration of methacholine	Between days 1 and 12 and between days 12 and 14 of both 14-day treatment periods	Shift in the provocative concentration of methacholine resulting in a 20% reduction in FEV1 (PC20) between days 1 and 12 and between days 12 and 14 of both 14-day treatment periods.

Trial Locations

Locations (3)

Vancouver General Hospital, The Lung Centre; 🇨🇦 Vancouver, British Columbia, Canada

McMaster University; 🇨🇦 Hamilton, Ontario, Canada

IUCPQ, Institut de cardiologie et de pneumologie de l'Hôpital Laval; 🇨🇦 Quebec, Canada